Department of Bioengineering, Department of Medicine, University of California, Los Angeles, Los Angeles, California 90095, USA; School of Biomedical Engineering and Med-X Research Institute, Shanghai Jiao Tong University, Shanghai 200240, China.
Keck School of Medicine of the University of Southern California, Los Angeles, CA 90033, USA; Department of Medicine, Cardiovascular Research Institute and Institute for Regeneration Medicine, University of California, San Francisco, CA 94143, USA.
J Mol Cell Cardiol. 2022 Oct;171:56-68. doi: 10.1016/j.yjmcc.2022.06.013. Epub 2022 Jul 18.
Cardiovascular disease is the leading cause of death in the world. Stem cell-based therapies have been widely investigated for cardiac regeneration in patients with heart failure or myocardial infarction (MI) and surged ahead on multiple fronts over the past two decades. To enhance cellular therapy for cardiac regeneration, numerous engineering techniques have been explored to engineer cells, develop novel scaffolds, make constructs, and deliver cells or their derivatives. This review summarizes the state-of-art stem cell-based therapeutics for cardiac regeneration and discusses the emerged bioengineering approaches toward the enhancement of therapeutic efficacy of stem cell therapies in cardiac repair. We cover the topics in stem cell source and engineering, followed by stem cell-based therapies such as cell aggregates and cell sheets, and biomaterial-mediated stem cell therapies such as stem cell delivery with injectable hydrogel, three-dimensional scaffolds, and microneedle patches. Finally, we discuss future directions and challenges of engineering stem cell therapies for clinical translation.
心血管疾病是世界范围内的主要死亡原因。基于干细胞的疗法已广泛应用于心力衰竭或心肌梗死(MI)患者的心脏再生,并在过去二十年中在多个方面取得了进展。为了增强心脏再生的细胞疗法,已经探索了许多工程技术来工程细胞、开发新型支架、制造构建体以及输送细胞或其衍生物。本文综述了基于干细胞的心脏再生治疗的最新进展,并讨论了新兴的生物工程方法,以提高干细胞疗法在心脏修复中的治疗效果。我们涵盖了干细胞来源和工程的主题,接着介绍了基于干细胞的疗法,如细胞聚集体和细胞片层,以及生物材料介导的干细胞疗法,如可注射水凝胶、三维支架和微针贴片介导的干细胞输送。最后,我们讨论了工程化干细胞疗法用于临床转化的未来方向和挑战。
J Mol Cell Cardiol. 2022-10
Acc Chem Res. 2019-5-24
Eur J Pharm Sci. 2023-6-1
J Tissue Eng Regen Med. 2016-1
Int J Pharm. 2017-5-25
Mayo Clin Proc. 2013-8
Adv Healthc Mater. 2023-4
Rev Cardiovasc Med. 2019-12-30
J Nanobiotechnology. 2025-8-19
Int J Mol Sci. 2025-5-23
Biology (Basel). 2025-3-20
Mater Today Bio. 2025-1-9
Front Bioeng Biotechnol. 2024-5-31
MedComm (2020). 2023-6-17